| Methods |
No minimal BP inclusion criteria; 24‐week total double‐blind treatment, report BP at week 4 of double‐blind treatment |
| Participants |
All patients (normotensive and hypertensive) with non‐insulin‐dependent diabetes mellitus:
Ramipril 1.25 mg: n=60(44 males,16 females); mean age=56(7) years; baseline SBP=147(15) mm Hg, DBP=90(6) mm Hg;
Placebo: n=62(50 males,12 females); mean age=58(7) years; baseline SBP=151(14) mm Hg, DBP=91(6) mm Hg;
Subgroup of patients with BP >/= 160/95 mm Hg:
Ramipril 1.25 mg: n=19; baseline SBP=156(12) mm Hg, DBP=95(4) mm Hg;
Placebo: n=24; baseline SBP=161(9) mm Hg, DBP=95(3) mm Hg |
| Interventions |
Ramipil 1.25 mg once daily;
Placebo |
| Outcomes |
Mean change from baseline in sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
Used week 4 BP data only; no minimal BP inclusion criteria, trial included both hypertensive and non‐hypertensive patients; Used BP data from subgroup with BP >/= 160/95 mm Hg; BP change and SD of change not reported; endpoint BP and SD reported; imputed endpoint SD of change; BP data from Table 5, p. 881; time of BP measurement not reported; Jadad score=4; funding source= Hoechst |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
